Jennifer K Chen, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chen’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A114854 · Current
Licensed to practise in California · since 2010 · expires 2028-10-31 · Johns Hopkins University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$45,384
Medicare paid this office $45,384 for 216 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 93 | $11,273 | $85 |
| Long return visit (40+ min) | 32 | $8,158 | $138 |
| Short return visit (20+ min) | 82 | $6,443 | $58 |
| Destruction of precancer skin growth, 1 growth | 61 | $3,622 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $3,349 | $105 |
See all 12 services
| Return visit (30+ min) | 93 | $11,273 | $85 |
| Long return visit (40+ min) | 32 | $8,158 | $138 |
| Short return visit (20+ min) | 82 | $6,443 | $58 |
| Destruction of precancer skin growth, 1 growth | 61 | $3,622 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $3,349 | $105 |
| Destruction of skin growth, 1-14 growths | 26 | $2,328 | $63 |
| Destruction of precancer skin growth, 15 or more growths | 18 | $2,249 | $86 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 22 | $1,686 | $73 |
| Biopsy of related skin growth, first growth | 32 | $922 | $26 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 38 | $920 | $15 |
| Destruction of precancer skin growth, 2-14 growths | 45 | $682 | $2 |
| Punch biopsy, first skin growth | 11 | $508 | $42 |
Procedures Medicare counted
| Removal of skin lesions | 285 | More than 82% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 111 | More than 77% of doctors who do this |
Who their Medicare patients are
216 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 11% · Women 54% · Also on Medicaid 16% · Health risk score 1.61. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 68% · Diabetes 28% · Coronary heart disease 27% · Chronic kidney disease 24% · Atrial fibrillation 22% · Heart failure 19% · Depression 19% · Cancer 18% · COPD 16% · Stroke 11% · Dementia 10%.
The office billed $244,417, Medicare allowed $61,168 and paid $45,384; for 1,018 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 216 | 1,018 | 74 | 1.61 | $244,417 | $45,384 |
| 2023 | 183 | 698 | 72 | 1.70 | $155,063 | $34,074 |
| 2022 | 222 | 819 | 72 | 1.63 | $206,569 | $38,592 |
| 2021 | 226 | 908 | 72 | 1.64 | $232,728 | $42,363 |
| 2020 | 252 | 786 | 72 | 1.50 | $186,481 | $29,521 |
| 2019 | 265 | 1,076 | 73 | 1.41 | $138,311 | $36,343 |
| 2018 | 219 | 761 | 73 | 1.48 | $80,911 | $27,544 |
| 2017 | 305 | 1,245 | 71 | 1.44 | $152,582 | $38,976 |
| 2016 | 268 | 1,078 | 72 | 1.48 | $120,873 | $34,031 |
| 2015 | 360 | 1,388 | 71 | 1.49 | $183,070 | $50,494 |
| 2014 | 306 | 1,010 | 71 | 1.45 | $135,786 | $38,402 |
| 2013 | 96 | 259 | 71 | 1.78 | $38,334 | $9,855 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 76 | $9,289 | $85 |
| Short return visit (20+ min) | 69 | $5,077 | $58 |
| Long return visit (40+ min) | 14 | $3,999 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $3,620 | $110 |
| Destruction of precancer skin growth, 1 growth | 51 | $3,078 | $49 |
| Destruction of skin growth, 1-14 growths | 28 | $2,191 | $64 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,285 | $76 |
| Biopsy of related skin growth, first growth | 23 | $617 | $22 |
| Destruction of precancer skin growth, 2-14 growths | 35 | $423 | $2 |
2022: 11 services
| Return visit (30+ min) | 80 | $8,660 | $76 |
| Long return visit (40+ min) | 34 | $8,594 | $121 |
| Short return visit (20+ min) | 73 | $5,168 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,717 | $94 |
| Destruction of precancer skin growth, 1 growth | 48 | $2,569 | $41 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 19 | $1,715 | $90 |
| Destruction of skin growth, 1-14 growths | 26 | $1,618 | $62 |
| New patient visit (45+ min) | 17 | $1,557 | $92 |
| Destruction of precancer skin growth, 15 or more growths | 11 | $1,169 | $84 |
| Biopsy of related skin growth, first growth | 36 | $790 | $19 |
| Destruction of precancer skin growth, 2-14 growths | 40 | $466 | $2 |
2021: 13 services
| Return visit (30+ min) | 97 | $12,088 | $82 |
| Long return visit (40+ min) | 39 | $7,054 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $4,200 | $95 |
| Short return visit (20+ min) | 51 | $3,458 | $52 |
| Destruction of precancer skin growth, 1 growth | 57 | $3,094 | $42 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 20 | $1,843 | $92 |
| New patient visit (45+ min) | 18 | $1,558 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,195 | $66 |
| Destruction of skin growth, 1-14 growths | 18 | $1,010 | $48 |
| Biopsy of related skin growth, first growth | 37 | $821 | $18 |
| Biopsy of related skin growth, each additional growth | 20 | $688 | $17 |
| Punch biopsy, first skin growth | 12 | $536 | $45 |
| Destruction of precancer skin growth, 2-14 growths | 41 | $479 | $2 |
2020: 16 services
| Return visit (30+ min) | 95 | $7,758 | $67 |
| Short return visit (20+ min) | 72 | $3,782 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,146 | $98 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 20 | $1,974 | $94 |
| Destruction of precancer skin growth, 1 growth | 41 | $1,921 | $42 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,421 | $68 |
| Long return visit (40+ min) | 12 | $1,286 | $92 |
| Return visit (30+ min) | 17 | $943 | $55 |
| New patient visit (30+ min) | 14 | $760 | $54 |
| Destruction of skin growth, 1-14 growths | 14 | $735 | $49 |
| Biopsy of related skin growth, first growth | 28 | $695 | $23 |
| Punch biopsy, first skin growth | 12 | $512 | $43 |
| New patient visit (15+ min) | 16 | $464 | $29 |
| Biopsy of related skin growth, each additional growth | 14 | $360 | $19 |
| Destruction of precancer skin growth, 2-14 growths | 29 | $323 | $2 |
| Biopsy of related skin growth, first growth | 11 | $203 | $18 |
2019: 17 services
| Return visit (30+ min) | 65 | $5,574 | $66 |
| Return visit (30+ min) | 53 | $4,130 | $65 |
| Short return visit (20+ min) | 56 | $3,249 | $41 |
| Destruction of precancer skin growth, 1 growth | 39 | $2,292 | $42 |
| Short return visit (20+ min) | 45 | $2,275 | $39 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,848 | $66 |
| Destruction of precancer skin growth, 1 growth | 34 | $1,678 | $37 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,544 | $91 |
| Destruction of precancer skin growth, 15 or more growths | 12 | $1,326 | $74 |
| Destruction of skin growth, 1-14 growths | 16 | $1,243 | $59 |
| Destruction of skin growth, 1-14 growths | 17 | $1,174 | $62 |
| New patient visit (30+ min) | 15 | $1,028 | $69 |
| Biopsy of related skin growth, first growth | 28 | $879 | $27 |
| New patient visit (30+ min) | 12 | $814 | $68 |
| Biopsy of related skin growth, first growth | 17 | $571 | $26 |
| Destruction of precancer skin growth, 2-14 growths | 33 | $449 | $2 |
| Destruction of precancer skin growth, 2-14 growths | 25 | $345 | $2 |
2018: 15 services
| Return visit (30+ min) | 75 | $6,131 | $67 |
| Short return visit (20+ min) | 82 | $4,127 | $45 |
| Destruction of skin growth, 1-14 growths | 30 | $2,235 | $62 |
| Destruction of precancer skin growth, 1 growth | 46 | $1,964 | $39 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,438 | $65 |
| Biopsy of single growth of skin and/or tissue | 36 | $1,199 | $32 |
| Return visit (30+ min) | 16 | $1,130 | $71 |
| Short return visit (20+ min) | 23 | $1,060 | $46 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $988 | $90 |
| Destruction of precancer skin growth, 1 growth | 16 | $687 | $43 |
| Biopsy of each additional growth of skin and/or tissue | 19 | $543 | $20 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $420 | $35 |
| Biopsy of single growth of skin and/or tissue | 12 | $402 | $34 |
| Destruction of precancer skin growth, 2-14 growths | 34 | $346 | $2 |
| Destruction of precancer skin growth, 2-14 growths | 11 | $115 | $2 |
2017: 13 services
| Return visit (30+ min) | 111 | $9,679 | $65 |
| Short return visit (20+ min) | 131 | $7,447 | $41 |
| Destruction of precancer skin growth, 1 growth | 87 | $4,416 | $37 |
| Destruction of skin growth, 1-14 growths | 43 | $3,031 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $2,656 | $65 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 21 | $1,974 | $90 |
| Biopsy of single growth of skin and/or tissue | 46 | $1,492 | $30 |
| New patient visit (30+ min) | 23 | $1,398 | $61 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 19 | $908 | $35 |
| Destruction of precancer skin growth, 2-14 growths | 71 | $830 | $2 |
| New patient visit (15+ min) | 18 | $717 | $40 |
| Biopsy of single growth of skin and/or tissue | 12 | $535 | $45 |
| Short return visit | 16 | $294 | $18 |
2016: 13 services
| Short return visit (20+ min) | 138 | $7,748 | $43 |
| Return visit (30+ min) | 87 | $7,148 | $63 |
| Destruction of precancer skin growth, 1 growth | 68 | $3,599 | $39 |
| Destruction of skin growth, 1-14 growths | 40 | $3,004 | $59 |
| Biopsy of single growth of skin and/or tissue | 52 | $1,991 | $34 |
| New patient visit (30+ min) | 30 | $1,799 | $60 |
| Destruction of precancer skin growth, 15 or more growths | 15 | $1,311 | $87 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,160 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,157 | $64 |
| Destruction of precancer skin growth, 2-14 growths | 54 | $773 | $2 |
| Biopsy of each additional growth of skin and/or tissue | 17 | $546 | $23 |
| New patient visit (15+ min) | 14 | $538 | $38 |
| Short return visit | 12 | $290 | $22 |
2015: 14 services
| Short return visit (20+ min) | 165 | $10,200 | $42 |
| Return visit (30+ min) | 66 | $6,820 | $67 |
| New patient visit (30+ min) | 88 | $5,690 | $65 |
| Destruction of skin growth, 1-14 growths | 56 | $5,232 | $63 |
| Destruction of precancer skin growth, 1 growth | 87 | $4,981 | $40 |
| Biopsy of single growth of skin and/or tissue | 70 | $2,913 | $34 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,770 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,683 | $65 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,434 | $90 |
| Long return visit (40+ min) | 12 | $1,392 | $93 |
| Biopsy of each additional growth of skin and/or tissue | 18 | $834 | $23 |
| Destruction of precancer skin growth, 2-14 growths | 67 | $775 | $2 |
| New patient visit (15+ min) | 18 | $655 | $36 |
| Short return visit | 15 | $636 | $23 |
2014: 14 services
| Short return visit (20+ min) | 146 | $9,927 | $43 |
| New patient visit (30+ min) | 89 | $5,336 | $60 |
| Return visit (30+ min) | 35 | $3,639 | $69 |
| Destruction of precancer skin growth, 1 growth | 62 | $3,563 | $45 |
| Destruction of skin growth, 1-14 growths | 33 | $2,846 | $63 |
| Biopsy of single growth of skin and/or tissue | 61 | $2,324 | $34 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,033 | $92 |
| Destruction of precancer skin growth, 15 or more growths | 13 | $1,497 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,345 | $64 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,339 | $89 |
| New patient visit (15+ min) | 26 | $1,112 | $43 |
| Destruction of precancer skin growth, 2-14 growths | 49 | $554 | $2 |
| Short return visit | 19 | $446 | $21 |
| Biopsy of each additional growth of skin and/or tissue | 11 | $289 | $21 |
2013: 6 services
| New patient visit (30+ min) | 35 | $2,176 | $62 |
| Short return visit (20+ min) | 33 | $1,929 | $44 |
| Biopsy of single growth of skin and/or tissue | 22 | $824 | $37 |
| Destruction of precancer skin growth, 1 growth | 15 | $726 | $45 |
| New patient visit (15+ min) | 13 | $564 | $43 |
| Destruction of precancer skin growth, 2-14 growths | 12 | $279 | $4 |
Medicaid work
$1,200 in 2022
Medicaid paid $1,200 for 27 billed services this clinician did in 2022, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 27 | $1,200 |
| 2022 | 27 | 1 | 13 | $1,200 |
Drugs they prescribed that Part D paid
$489,131
Pharmacies billed $489,131 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 502) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
412 generic and 90 brand-name prescriptions · $489,131 in drug cost · 15 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 33 | $130,563 | $3,956 |
| Dupixent | 13 | $87,452 | $6,727 |
| Calcipotriene-Betamethasone | 11 | $3,966 | $361 |
| Tacrolimus | 28 | $2,123 | $76 |
| Desonide | 22 | $1,715 | $78 |
See all 15 drugs
| Dupixent | 33 | $130,563 | $3,956 |
| Dupixent | 13 | $87,452 | $6,727 |
| Calcipotriene-Betamethasone | 11 | $3,966 | $361 |
| Tacrolimus | 28 | $2,123 | $76 |
| Desonide | 22 | $1,715 | $78 |
| Clobetasol Propionate | 24 | $1,343 | $56 |
| Fluocinonide | 32 | $1,124 | $35 |
| Ketoconazole | 70 | $1,043 | $15 |
| Clindamycin Phosphate | 11 | $494 | $45 |
| Doxycycline Hyclate | 14 | $404 | $29 |
| Triamcinolone Acetonide | 41 | $399 | $10 |
| Hydrocortisone | 30 | $368 | $12 |
| Metronidazole | 12 | $315 | $26 |
| Spironolactone | 21 | $133 | $6 |
| Prednisone | 16 | $7 | $0 |
Year by year
| 2024 | 502 | 104 | 0% (0) | 18% | $489,131 |
| 2023 | 363 | 75 | 0% (0) | 10% | $223,636 |
| 2022 | 513 | 115 | 0% (0) | 13% | $335,925 |
| 2021 | 413 | 111 | 0% (0) | 20% | $269,807 |
| 2020 | 317 | 110 | 0% (0) | 10% | $39,980 |
| 2019 | 449 | 134 | 0% (0) | 12% | $164,808 |
| 2018 | 344 | 112 | 0% (0) | 11% | $90,133 |
| 2017 | 432 | 136 | 0% (0) | 19% | $170,452 |
| 2016 | 453 | 142 | None | 22% | $179,777 |
| 2015 | 599 | 185 | None | 19% | $195,455 |
| 2014 | 381 | 128 | None | 26% | $124,502 |
| 2013 | 118 | 68 | None | 17% | $9,805 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Dupixent | 11 | $50,713 | $4,610 |
| Atovaquone | 11 | $7,513 | $683 |
| Tacrolimus | 20 | $5,302 | $265 |
| Clobetasol Propionate | 16 | $2,967 | $185 |
| Fluocinonide | 19 | $1,216 | $64 |
| Metronidazole | 18 | $1,026 | $57 |
| Sotalol | 14 | $807 | $58 |
| Ketoconazole | 31 | $781 | $25 |
| Triamcinolone Acetonide | 48 | $543 | $11 |
| Hydrocortisone | 15 | $226 | $15 |
2022: 17 drugs
| Dupixent | 22 | $77,129 | $3,506 |
| Atovaquone | 11 | $9,296 | $845 |
| Tacrolimus | 30 | $5,922 | $197 |
| Calcipotriene | 12 | $2,258 | $188 |
| Fluocinonide | 37 | $2,067 | $56 |
| Clobetasol Propionate | 19 | $2,035 | $107 |
| Doxycycline Hyclate | 14 | $1,692 | $121 |
| Fluorouracil | 15 | $1,342 | $89 |
| Nystatin | 15 | $1,292 | $86 |
| Triamcinolone Acetonide | 75 | $986 | $13 |
| Tretinoin | 13 | $876 | $67 |
| Ketoconazole | 43 | $769 | $18 |
| Desonide | 14 | $752 | $54 |
| Clindamycin Phosphate | 11 | $473 | $43 |
| Econazole Nitrate | 12 | $179 | $15 |
| Prednisone | 17 | $144 | $8 |
| Hydrocortisone | 19 | $105 | $6 |
2021: 17 drugs
| Dupixent | 35 | $116,117 | $3,318 |
| Doxepin | 12 | $5,587 | $466 |
| Desoximetasone | 15 | $3,511 | $234 |
| Tacrolimus | 17 | $2,669 | $157 |
| Fluocinonide | 34 | $2,451 | $72 |
| Tretinoin | 12 | $1,228 | $102 |
| Fluorouracil | 13 | $870 | $67 |
| Desonide | 18 | $774 | $43 |
| Ketoconazole | 41 | $661 | $16 |
| Clobetasol Propionate | 12 | $567 | $47 |
| Triamcinolone Acetonide | 37 | $468 | $13 |
| Alclometasone Dipropionate | 11 | $460 | $42 |
| Econazole Nitrate | 15 | $358 | $24 |
| Clotrimazole | 11 | $348 | $32 |
| Hydroxychloroquine Sulfate | 14 | $295 | $21 |
| Doxycycline Hyclate | 13 | $215 | $17 |
| Hydrocortisone | 13 | $54 | $4 |
2020: 8 drugs
| Fluorouracil | 21 | $2,566 | $122 |
| Fluocinonide | 31 | $1,670 | $54 |
| Calcipotriene | 14 | $1,440 | $103 |
| Tretinoin | 14 | $1,303 | $93 |
| Ketoconazole | 22 | $620 | $28 |
| Triamcinolone Acetonide | 40 | $542 | $14 |
| Valacyclovir | 11 | $210 | $19 |
| Hydrocortisone | 28 | $140 | $5 |
2019: 14 drugs
| Doxepin | 13 | $11,410 | $878 |
| Ketoconazole | 46 | $6,856 | $149 |
| Fluorouracil | 26 | $3,549 | $136 |
| Tacrolimus | 12 | $2,802 | $233 |
| Tretinoin | 17 | $2,337 | $137 |
| Fluocinonide | 28 | $1,574 | $56 |
| Clobetasol Propionate | 17 | $1,252 | $74 |
| Clindamycin Phosphate | 22 | $1,171 | $53 |
| Triamcinolone Acetonide | 77 | $979 | $13 |
| Metronidazole | 12 | $863 | $72 |
| Hydroxyzine | 16 | $509 | $32 |
| Gabapentin | 15 | $248 | $17 |
| Hydrocortisone | 46 | $233 | $5 |
| Valacyclovir | 12 | $137 | $11 |
2018: 11 drugs
| Ketoconazole | 46 | $9,028 | $196 |
| Clobetasol Propionate | 19 | $2,557 | $135 |
| Fluorouracil | 16 | $2,245 | $140 |
| Fluocinonide | 23 | $1,461 | $64 |
| Metronidazole | 13 | $1,208 | $93 |
| Desonide | 11 | $911 | $83 |
| Hydroxychloroquine Sulfate | 12 | $822 | $69 |
| Triamcinolone Acetonide | 56 | $760 | $14 |
| Clindamycin Phosphate | 11 | $558 | $51 |
| Doxycycline Hyclate | 14 | $331 | $24 |
| Hydrocortisone | 26 | $143 | $5 |
2017: 12 drugs
| Tacrolimus | 19 | $4,928 | $259 |
| Fluorouracil | 25 | $2,612 | $104 |
| Fluocinonide | 32 | $2,302 | $72 |
| Clindamycin Phosphate | 27 | $2,261 | $84 |
| Clobetasol Propionate | 11 | $2,170 | $197 |
| Ketoconazole | 30 | $1,926 | $64 |
| Doxepin | 12 | $1,660 | $138 |
| Hydroxychloroquine Sulfate | 27 | $1,228 | $45 |
| Triamcinolone Acetonide | 67 | $1,071 | $16 |
| Methotrexate | 12 | $686 | $57 |
| Hydrocortisone | 18 | $320 | $18 |
| Gabapentin | 12 | $108 | $9 |
2016: 13 drugs
| Elidel | 12 | $6,675 | $556 |
| Clobetasol Propionate | 25 | $5,279 | $211 |
| Desonide | 26 | $4,478 | $172 |
| Fluocinonide | 33 | $2,458 | $74 |
| Hydroxychloroquine Sulfate | 23 | $2,437 | $106 |
| Tretinoin | 23 | $2,331 | $101 |
| Doxycycline Hyclate | 20 | $1,813 | $91 |
| Fluorouracil | 12 | $1,631 | $136 |
| Triamcinolone Acetonide | 51 | $1,106 | $22 |
| Clindamycin Phosphate | 14 | $894 | $64 |
| Ketoconazole | 23 | $635 | $28 |
| Hydrocortisone | 34 | $244 | $7 |
| Gabapentin | 21 | $231 | $11 |
2015: 17 drugs
| Clobetasol Propionate | 48 | $15,339 | $320 |
| Desonide | 30 | $4,656 | $155 |
| Fluorouracil | 18 | $3,103 | $172 |
| Fluocinonide | 26 | $2,035 | $78 |
| Triamcinolone Acetonide | 80 | $1,678 | $21 |
| Ketoconazole | 40 | $1,583 | $40 |
| Hydroxychloroquine Sulfate | 11 | $1,528 | $139 |
| Doxycycline Hyclate | 12 | $1,455 | $121 |
| Clindamycin Phosphate | 20 | $995 | $50 |
| Methotrexate | 14 | $627 | $45 |
| Nystop | 13 | $607 | $47 |
| Carbidopa-Levodopa | 14 | $514 | $37 |
| Ciclopirox | 13 | $442 | $34 |
| Doxepin | 15 | $190 | $13 |
| Hydroxyzine | 19 | $167 | $9 |
| Prednisone | 15 | $141 | $9 |
| Hydrocortisone | 20 | $130 | $7 |
2014: 11 drugs
| Humira | 21 | $56,844 | $2,707 |
| Taclonex | 11 | $21,089 | $1,917 |
| Fluorouracil | 24 | $4,317 | $180 |
| Fluocinolone Acetonide | 16 | $2,691 | $168 |
| Clobetasol Propionate | 22 | $2,526 | $115 |
| Desonide | 13 | $1,925 | $148 |
| Clindamycin Phosphate | 15 | $1,241 | $83 |
| Fluocinonide | 14 | $1,131 | $81 |
| Tretinoin | 12 | $1,093 | $91 |
| Triamcinolone Acetonide | 44 | $682 | $16 |
| Ciclopirox | 14 | $460 | $33 |
2013: 1 drug
| Triamcinolone Acetonide | 19 | $408 | $21 |
Money from drug and device companies
$171 in 2025
| 2025 | 3 | 3 | None | $171 |
| 2024 | 2 | 2 | $800 | $925 |
| 2023 | 1 | 1 | None | $15 |
| 2020 | 1 | 1 | None | $126 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $99 | 1 payment
|
| LEO Pharma | Adbry | $49 | 1 payment
|
| Abbvie | Skyrizi | $22 | 1 payment
|
See all 3 published payments
| Abbvie | Meals · 2025-04-10 | Skyrizi | $22 |
| LEO Pharma | Meals · 2025-03-08 | Adbry | $49 |
| Janssen Biotech | Education · 2025-01-03 | Tremfya | $99 |
See earlier years (2024, 2023, 2020)
2024: $925
| Almirall | None | $800 | 1 payment
|
| Verrica Pharmaceuticals | Ycanth | $125 | 1 payment
|
2023: $15
| Pfizer | Cibinqo | $15 | 1 payment
|
2020: $126
| Allergan | None | $126 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1184851297
- Licence
- CA A114854California A114854: Current · expires 2028-10-31
- Trained
- Johns Hopkins University School of Medicine, 2009
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 450 Broadway St, Pavilion C-242, Redwood City, CA, 94063
- NPI first listed
- 2009-06-16
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 450 Broadway St, Redwood City, CA, 94063